Actively Recruiting
Comparing QLC5508 Plus QL2107 Versus Tislelizumab with Platinum Chemotherapy in Treatment-Nave Extensive-Stage Small Cell Lung Cancer A Phase III Randomized Open-Label Study
Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2026-10-30
556
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of two treatment combinations as first-line therapy for participants with extensive-stage small cell lung cancer. This Phase III, randomized, open-label, multicenter study compares QLC5508 combined with QL2107 against Tislelizumab plus platinum-based chemotherapy. The trial aims to understand which treatment offers better overall survival outcomes for this condition. Participants receive intravenous infusions every three weeks. One group is treated with QLC5508 and QL2107, continuing until disease progression or unacceptable side effects, with QL2107 limited to a maximum of two years. The other group receives Tislelizumab plus platinum-based chemotherapy either carboplatin or cisplatin and etoposide, also given every three weeks, with chemotherapy administered for up to four cycles and Tislelizumab up to two years. During the study, participants are regularly monitored for overall survival, progression-free survival, response rates, and adverse events for up to approximately 36 months. Researchers will assess disease control, response duration, and survival rates at intervals of six, twelve, and twenty-four months. Participants will undergo clinical evaluations and safety assessments throughout the treatment and follow-up periods, which together span several years until study completion.
CONDITIONS
Brief Title
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Research Team
H
Haiying Yu, Bachelor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here